• News
  • SAN DIEGO
  • General

Calbiotech to expand its manufacturing capabilities

San Diego-based Calbiotech announced Tuesday it is expanding its manufacturing capabilities with the addition of a new GMP monoclonal antibody production facility and the hire of Dr. Jimin Wang, vice president of research and development, who will lead the project.

Antibody production will cater to both Calbiotech and market needs, leveraging strong ties to research and academic groups to identify new markers, produce antibodies and develop assays.

Calbiotech will also supplement its strong assay development and contract manufacturing services with custom antibody production services from its GMP facility.

“Calbiotech is excited to break into the antibody sphere with our first production anticipated for release in 2014, and we are thrilled to have Dr. Wang become an integral part of our team,” said David Barka, Calbiotech vice president.

Wang obtained an M.D. and Ph.D. from Shanghai Second Medical University and has more than 15 years of experience working on antibody and assays development. Most recently, he managed the Hybridoma facility for antibody production and a team focused on assay development including cytokine and signaling assays in ELISAs and Luminex platforms at BioSource/Invitrogen.

Calbiotech custom develops and manufactures immunoassay products used by major reference labs, universities and research centers around the world. The company has grown its holdings in recent years, which include Moduline Systems and Calbiotech Veterinary Diagnostics, formed after Calbiotech acquired the veterinary diagnostics division of Meridian Life Sciences Inc.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.